An improved understanding of the mechanisms regulating autophagy in macrophages may identify methods to modulate © 2017 American Heart Association, Inc. 
I n atherosclerosis, lipid-laden macrophage foam cells accumulate in the artery wall, where they fuel chronic inflammation that promotes plaque formation. 1 Autophagy plays a key role in the maintenance of cellular lipid homeostasis, and its dysregulation results in pathophysiological processes, including atherosclerosis. 2, 3 Autophagy of cytoplasmic lipid droplets, also known as lipophagy, catabolizes stored triglycerides and promotes fatty acid oxidation to maintain cellular energy homeostasis. 4 It also protects against the detrimental effects of cellular cholesterol accumulation in macrophages by delivering excess cholesterol, stored as cholesterol esters in lipid droplets, to lysosomes where they are hydrolyzed by lysosomal acid lipase to free cholesterol and effluxed from the cell. 5 In addition, autophagy and lysosomal degradation contribute to the response to efferocytosis of apoptotic cells, 6, 7 which presents a lipid-loading stress on the engulfing cell. Recent studies have demonstrated that autophagy becomes progressively impaired in atherosclerosis, 8 and compromised autophagy in macrophages has been shown to account for many proatherosclerotic processes, including impaired cholesterol metabolism, 5, 9 defective efferocytosis, 10 and activation of the inflammasome. 8 These studies suggest that inducing autophagy may promote regression of atherosclerotic plaques, yet this remains to be directly tested.
autophagy function and restore homeostasis in the case of autophagy dysfunction in atherosclerosis. Recent studies have shown that microRNAs (miRNAs) regulate autophagy through post-transcriptional repression of autophagy-related genes (Atg) or upstream effectors (BECN1, mTOR, and ULK1). [11] [12] [13] miRNAs target mRNAs for translational repression or degradation by binding to complementary regions in the 3′ untranslated region of mRNAs.
14 Many miRNAs are highly conserved among eukaryotic species and seem to have evolved as fine-tuners of gene expression that can simultaneously repress multiple, related genes in a biological pathway. 15 As such, miRNA modulation using either miRNA inhibitors or mimics is being actively investigated as a means to therapeutically target pathways in disease. However, our understanding of how miRNAs regulate autophagy in pathological settings, such as atherosclerosis, remains incomplete.
Studies from our group and others have identified miRNA-33 (miR-33) as a key regulator of metabolic gene pathways involved in cholesterol and fatty acid homeostasis. 14 In humans, miR-33a and miR-33b are intronic miRNAs that are coexpressed with their host genes, SREBF2 and SREBF1, which code for transcription factors that regulate cholesterol and fatty acid synthesis/uptake. [16] [17] [18] Thus, transcription of SREBF2 and SREBF1 also results in expression of miR-33a and miR-33b, which cooperate with their host genes to balance cellular lipid levels by repressing genes that oppose SREBPregulated pathways, such those involved in cholesterol efflux (ABCA1 [ATP-binding cassette transporter A1] and ABCG1 [ATP-binding cassette transporter G1]) [16] [17] [18] and fatty acid oxidation (HADHB, CROT, CPT1A, and PRKAA1). [19] [20] [21] Mice have only 1 copy of miR-33 located within Srebf2, and like its human counterpart, it is coregulated with its host gene. [16] [17] [18] In particular, miR-33 is a potent inhibitor of the cholesterol transporter ABCA1, which contributes to reverse cholesterol transport by mediating both cellular cholesterol efflux and the genesis of high-density lipoproteins. [16] [17] [18] 20, 22, 23 Inhibition of miR-33 has been shown to increase plasma levels of highdensity lipoprotein in mice [16] [17] [18] and primates 24, 25 and to reduce plaque size and inflammation in mouse models of atherosclerosis. [26] [27] [28] [29] Recently, we showed that miR-33 expression is induced by the intracellular pathogen Mycobacterium tuberculosis, 30 which survives within macrophages by evading autophagy-mediated degradation and promoting the accumulation of lipid bodies that serve as a nutrient source for the bacterium. 30 which in turn, enables intracellular survival of the bacterium. 30 These findings have reinforced the notion that miR-33 orchestrates gene pathway regulation as a means to fine-tune cellular metabolism. As autophagy regulates the catabolism of lipid droplet-stored cholesterol esters 5 in addition to mediating bacterial delivery to the lysosome (xenophagy), we hypothesized that miR-33 may restrict the mobilization of cholesterol destined for ABCA1-mediated efflux by repressing autophagy.
Here, we show that miR-33 reduces lipid droplet catabolism in macrophage foam cells by repressing key autophagy effectors (Atg5, Atg12, Map1lc3b, Prkaa1, and Lamp1) and transcriptional regulators (FOXO3 and TFEB). miR-33 silencing promotes lipid droplet mobilization in macrophage foam cells, a process that is upstream of ABCA1-dependent cholesterol efflux. Notably, the ability of miR-33 inhibitors to enhance cholesterol efflux is lost in macrophages deficient in autophagy, despite derepression of ABCA1 expression, highlighting the important contribution of this pathway. Finally, we show that miR-33 inhibition in atherosclerotic mice restores defective autophagy in the aorta and in macrophages of atherosclerotic plaques. Together, these results provide a better understanding of the mechanisms by which miR-33 regulates cellular cholesterol metabolism and identify miR-33 inhibition as a therapeutic means to enhance autophagy in atherosclerosis.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

miR-33 Regulates Lipid Droplet Abundance via Lysosomal Cholesterol Efflux
Autophagy plays a critical role in the delivery of lipid droplets to the lysosome, where lipid droplet-associated neutral lipids are catabolized. To investigate whether miR-33 affects this process, we used coherent anti-Stokes Raman scattering microscopy to perform label-free imaging of lipid droplets in macrophages. Peritoneal macrophages transfected with miR-33 and loaded with acetylated low-density lipoprotein for 24 hours showed increased lipid droplet burden and volume compared with macrophage transfected with control mimic ( Figure 1A ), suggesting that miR-33 represses lipid droplet catabolism. Macrophage autophagy delivers lipid droplets to the lysosome where stored cholesterol esters are hydrolyzed by lysosomal acid lipase to free cholesterol, 5 which can then be effluxed from the cell. This pathway can be distinguished from the actions of cytoplasmic neutral cholesteryl ester hydrolases using inhibitors that disrupt lysosomal (chloroquine) or neutral (paraoxon) lipolysis. Thus, to determine whether miR-33 regulation of autophagy contributes to its Figure 1B ), indicating a requirement for lysosomal function. Furthermore, miR-33 inhibition increased cholesterol efflux in mouse peritoneal macrophages treated with vehicle or paraoxon ( Figure 1C ), but not chloroquine, suggesting that miR-33 regulates cholesterol availability for efflux by the autophagy pathway.
miR-33 Regulates Lipid Droplet Clearance In Vivo via Autophagy
Recent studies from our group showed that in M tuberculosis-infected macrophages, miR-33 reduces autophagy-mediated bacterial killing by repressing autophagy effector genes (Atg5, Lamp1, and Prkaa1) and 5′ AMP-activated protein kinase-activated transcription factors (Foxo3 and Tcfeb).
30
To test whether miR-33 represses autophagy in atherogenic macrophages, we used a model of in vivo foam cell formation, in which we injected hypercholesterolemic Apoe −/− mice with thioglycollate intraperitoneally to elicit the recruitment of peritoneal macrophages and treated mice with control or anti-miR-33 oligonucleotides for 72 hours ( Figure 2A ). Macrophages isolated from anti-miR-33-treated mice showed higher mRNA levels of the miR-33 target genes Atg5, Lamp1, Prkaa1, and Abca1, but not control genes (Apoe and Cd68), compared with macrophages from mice treated with control anti-miR ( Figure 2B ), thus confirming repression of these genes by endogenous miR-33 in macrophage foam cells. In addition, macrophages from anti-miR-33-treated mice showed higher mRNA levels of Foxo3 and Tcfeb, as well as mRNAs for autophagy-related genes that they regulate (FOXO3: Atg4b, Atg12, and Map1lc3b; TFEB: Ctsb, Lipa, and Uvrag), compared with macrophages from control anti-miR-treated mice ( Figure 2C ). Consistent with the collective increase in expression of these autophagy genes, Western blotting revealed an increase in protein levels of the autophagosome marker LC3 (microtubule-associated protein 1A/1B light chain B) and reduced levels of the chaperone protein p62 (sequestosome-1)/ SQSTM1 (which is degraded by autophagy 31 ) in macrophages isolated from mice treated with anti-miR-33 compared with control anti-miR ( Figure 2D ). Immunofluorescent staining for the lipid droplet marker adipophilin showed that macrophages isolated from control anti-miR-treated Apoe −/− mice contained abundant adipophilin-positive cytoplasmic neutral lipid droplets, consistent with foam cells, and this was greatly reduced in macrophages from anti-miR-33-treated mice ( Figure 2E) . Notably, the decrease in lipid droplets in macrophages from anti-miR-33-treated mice was associated with an increase in punctate LC3 staining, consistent with an increase in autophagosomes, and colocalization of LC3 and BODIPY + punctate indicative of autophagic degradation of lipid droplets ( Figure 2F ).
Regulation of Cholesterol Homeostasis by miR-33 Is Dependant on Autophagy
To test whether miR-33 regulation of autophagy is essential for its effects on cholesterol efflux, we performed experiments in Atg5 −/− autophagy-deficient macrophages. Compared with wild-type bone marrow-derived macrophages (BMDMs), cholesterol efflux to apo AI is reduced by ≈40% in Atg5 −/− BMDMs, which represents the contribution of autophagy to the generation of free cholesterol for efflux, with the balance generated by neutral cholesterol ester hydrolysis. Transfection of wild-type BMDMs with miR-33 reduced cholesterol efflux to apo AI compared with control mimic-treated cells, whereas 
miR-33 overexpression failed to decrease cholesterol efflux in
Atg5
−/− BMDMs ( Figure 3A) . Correspondingly, transfection of wild-type BMDMs with anti-miR-33 increased cholesterol efflux to apo AI ( Figure 3B ) and promoted the dissipation of cytoplasmic BODIPY + lipid droplets ( Figure 3C and 3D), whereas these effects were absent in similarly treated Atg5 −/− BMDMs. Notably, wild-type and Atg5 −/− BMDMs transfected with anti-miR-33 showed equivalent increases in Abca1 mRNA ( Figure 3E ), indicating that miR-33 regulation of autophagy acts upstream of ABCA1 to control cholesterol availability for efflux.
Antagonism of miR-33 Promotes Autophagy in Atherosclerotic Plaques
Recent studies indicate that autophagy becomes impaired in atherosclerosis, and its dysfunction contributes to vascular inflammation and plaque progression. 8, 10 To investigate whether miR-33 inhibition could restore autophagy in atherosclerotic mice, we fed Ldlr −/− mice a western diet for 14 weeks to establish atherosclerotic plaques, and then treated mice with control anti-miR or anti-miR-33 for 4 weeks on a chow diet ( Figure 4A ). Using this model, we previously reported that anti-miR-33 treatment reduced atherosclerotic plaque size by 35%, compared with control anti-miR. 27 To evaluate autophagy in these mice, we first measured p62 protein because this chaperone protein has been shown to accumulate in the aorta with atherosclerosis progression. 8 Aortic lysates from control anti-miR-treated Ldlr −/− mice showed high levels of p62 protein, consistent with defective autophagy ( Figure 4B) . Notably, treatment with anti-miR-33 reduced aortic p62 protein levels by ≈40% ( Figure 4B ). Similarly, immunofluorescent staining for p62 in cross sections of the aortic root showed markedly less p62 in CD68 + plaque macrophages of anti-miR-33-treated mice compared with control anti-miR-treated mice ( Figure 4C and 4D) . Consistent with the reduced accumulation of p62 in anti-miR-33-treated mice, we observed an increase in LC3 staining in plaques from these mice, compared with control anti-miR-treated mice ( Figure 5A ). Whereas CD68 + plaque macrophages from control anti-miR-treated mice showed little LC3 staining, we observed abundant LC3 staining in CD68 + macrophages in plaques of anti-miR-33-treated mice ( Figure 5A and 5B), which combined with our observation of reduced p62 levels suggests elevated autophagy flux in plaques of anti-miR-33-treated mice. Interestingly, we also observed some LC3 staining in cells that did not express CD68, which are likely of smooth muscle cell origin ( Figure 5A and 5B). Taken together, these data indicate that inhibition of endogenous miR-33 in vivo restores autophagy function in atherosclerotic plaques.
miR-33 Regulates Efferocytosis in Atherosclerosis
In addition to the improvement in markers of autophagy, we observed that plaques from anti-miR-33-treated mice had reduced necrotic area compared with plaques from control anti-miR-treated mice ( Figure 6A ). As plaque necrotic core formation is thought to result from defective clearance of apoptotic cells or efferocytosis, 6 and autophagy can promote efferocytosis by regulating the efficient recognition of apoptotic cells and degradation of phagocytosed material, 10,32-34 we investigated whether miR-33 alters these processes. To test the impact of endogenous miR-33 on efferocytosis, we transfected BMDMs with anti-miR-33 or control anti-miR and measured their uptake of fluorescently labeled apoptotic Jurkat cells. Inhibition of miR-33 increased internalization of apoptotic cells by BMDMs by 30% compared with control anti-miR treatment ( Figure 6B ). Inhibition of miR-33 also increased efferocytotic capacity, as evidenced by a greater number of apoptotic cells per macrophage in anti-miR-33 compared with control anti-miR-treated BMDMs ( Figure 6C) . Notably, these effects were dependent on ATG5 because miR-33 inhibition failed to increase efferocytosis in Atg5 −/− macrophages ( Figure 6D ). As we observed an increase in TFEB on miR-33 inhibition, we postulated that this may increase lysosome biogenesis and, thus, the degradative capacity of anti-miR-33-treated macrophages. Indeed, we observed an increase in LAMP1 (lysosomal-associated membrane protein 1)-positive lysosomes in anti-miR-33 compared with control anti-miRtreated BMDMs ( Figure 6E ). Consistent with an increase in lysosomal function, anti-miR-33-treated macrophages incubated with apoptotic cells contained a greater number of small diffuse apoptotic bodies and fewer intact intracellular apoptotic cells than control anti-miR-treated BMDMs ( Figure 6F ). Together, these data suggest that by enhancing autophagy and lysosomal biogenesis, miR-33 inhibition increases macrophage apoptotic cell clearance and digestion of apoptotic cargo, which likely contribute to its beneficial effects on atherosclerosis.
Discussion
In this study, we show that miR-33 has potent effects on autophagy and lysosomal function that reinforce its targeting of cholesterol efflux and reverse cholesterol transport gene pathways to mediate cholesterol homeostasis. Previous studies by our group and others established miR-33 as a potent inhibitor of cholesterol efflux and reverse cholesterol transport 18,27 through its targeting of key genes involved in cholesterol transport (Abca1 and Abcg1 [16] [17] [18] ), biliary excretion (Atp8b1 and Abcb11
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), and intracellular trafficking (Npc1 18 and Osbpl6
36
). We now show that by targeting key autophagy regulators and effectors in macrophages, miR-33 reduces the catabolism of lipid droplets by lysosomes, a process that generates free cholesterol for efflux. Notably, miR-33 regulation of lipophagy lies upstream of its effects on ABCA1-dependent cholesterol efflux because miR-33 inhibitors fail to increase cholesterol efflux to apo AI in the presence of genetic or chemical inhibitors of autophagy, despite increases in macrophage ABCA1 expression. These findings suggest that miR-33 primarily restricts the generation of free cholesterol via the acid lipolysis pathway but does not affect neutral cholesterol ester hydrolysis. Together, these findings underscore the critical contribution of miR-33 regulation of autophagy to its effects on cellular lipid metabolism. They also highlight the importance of miRNAs as orchestrators of pathway control that can have profound effects on biological processes by targeting multiples genes within related pathways.
Recent studies in mouse models of atherosclerosis have shown that macrophage autophagy becomes defective with disease progression, resulting in accelerated atherogenesis. 8, 10 These studies suggest that mechanisms that increase autophagy in plaque macrophages may restore defective lipid metabolism and reduce inflammation, leading to plaque regression. We previously showed that miR-33 expression is increased in human atherosclerotic plaques, and that miR-33 expression is particularly abundant in proinflammatory M1 macrophages-the predominant macrophage phenotype in progressing plaques-when compared with proresolving M2 macrophages, 26 raising the possibility that miR-33 may contribute to autophagy inhibition in atherosclerosis. Indeed, we show herein that treating hypercholesterolemic mice with miR-33 inhibitors increases autophagosome formation and reduces lipid droplet burden in macrophage foam cells, indicating repression of these processes by miR-33 in vivo. Furthermore, treating atherosclerotic Ldlr −/− mice with miR-33 inhibitors for 4 weeks reduced p62 accumulation in the aorta and in plaque macrophages and also increased LC3 levels in plaques, consistent with improved autophagy. These findings suggest that miR-33 inhibition may be a promising strategy to reverse autophagy dysfunction in atherosclerosis. Importantly, inhibition of miR-33 not only increases expression of its direct target genes in the autophagy pathway (mouse: Atg5, Lamp1, and Prkaa1; human: ATG5, ATG12, MAP1LC3B, PRKAA1, and LAMP1) 30 but also promotes 5′ AMP-activated protein kinase-dependent activation of the FOXO3 and TFEB transcription factors, 30 which sustains autophagy via an autoregulatory feedfoward loop. 31, 37 Although our study does not discriminate the contribution of miR-33's effects on transcriptional regulation of autophagy from its repression of its direct target genes in the autophagy pathway, it highlights the roles of miRNAs as pathway regulators, which can have profound effects on biological processes by targeting multiple genes within a related pathway.
By regulating 5′ AMP-activated protein kinase-dependent activation of FOXO3 and TFEB, miR-33 may have broad effects on lysosomal trafficking and function that reinforce its targeting of key autophagy effector genes. We recently showed that miR-33 inhibition increases TFEB protein levels and its translocation to the nucleus, 30 where activated TFEB promotes the expression of a network of genes involved in lysosome and autophagosome biogenesis and function. 38, 39 We show herein that treatment of Ldlr −/− mice with anti-miR-33 increases expression of TFEB and its transcriptional targets Ctsb (cathepsin B), Lipa (lysosomal acid lipase), and Uvrag (UV radiation resistance-associated gene) in macrophage foam cells. TFEB overexpression in atherosclerotic macrophages has been reported to enhance prodegradative responses and rescue macrophage defects seen with atherogenic lipid loading, including lysosomal dysfunction, inflammasome activation, and polyubiquitinated protein aggregation. 40 Thus, the potential of miR-33 inhibitors to simultaneously increase expression of genes in the autophagy pathway and activation of TFEB represents a powerful approach to enhance macrophage function in atherosclerosis.
Stimulation of the autophagolysosomal pathway in macrophages through miR-33 inhibition is likely to promote multiple protective functions that limit plaque progression, including enhancing lipid droplet catabolism and ABCA1-dependent efflux, reducing inflammasome activation, and promoting the efferocytosis of apoptotic cells.
8,10,41 Indeed, we previously showed that plaques from atherosclerotic Ldlr −/− mice treated with miR-33 inhibitors for 4 weeks have reduced plaque size, lipid content, and inflammation compared with plaques from control anti-miR-treated mice. 26, 27 Although these beneficial effects of miR-33 inhibition were initially attributed to increased levels of plasma high-density lipoprotein cholesterol and macrophage reverse cholesterol transport, 27 our current data reveal a previously unappreciated effect on plaque macrophage autophagy that would increase both cholesterol mobilization for efflux and apoptotic cell clearance. Efferocytosis becomes impaired in atherosclerotic plaques, and if not cleared, apoptotic cells undergo secondary necrosis, leading to the formation of necrotic cores that threaten plaque stability. 42 We find that inhibition of miR-33 in vitro promotes macrophage efferocytosis, lysosomal biogenesis, and degradation of apoptotic material-processes that would stimulate tissue repair and plaque regression. Given that ATG5-deficient macrophages are capable of phagocytosing apoptotic cells at similar rates to that of wild type, 7, 34 the increase in ATG5-mediated efferocytosis in anti-miR-33-treated macrophages relative to wild type may be attributable to an enhanced degradative capacity of these cells and increased LC3. Indeed, LC3-associated phagocytosis was recently shown to be activated in response to engulfment of apoptotic cells and to promote degradation of the endocytosed material. 33, 34 This process is distinct from the classical autophagy pathway but requires ATG5. 33 Consistent with an improvement in efferocytosis with antimiR-33 treatment, we find that atherosclerotic Ldlr −/− mice treated with miR-33 inhibitors have reduced plaque necrotic area compared with control anti-miR-treated mice, and similar findings were also observed in diabetic Ldlr −/− mice treated with anti-miR-33. 43 These beneficial effects related to anti-miR-33-dependent derepression of the autophagy pathway are likely to work in concert with anti-miR-33's other known antiatherosclerotic mechanisms (eg, increasing high-density lipoprotein, reverse cholesterol transport, mitochondrial biogenesis, 44 fatty acid oxidation, 20, 23 and M2 macrophage polarization 26 ). Collectively, our data provide insight into the mechanisms by which miR-33 regulates cellular cholesterol homeostasis, and how its expression during atherogenesis may contribute to disease progression. Mir33 (MIR33A in humans) is embedded within an intron of the Srebf2 gene and is transcriptionally upregulated with its host gene under conditions of low sterol. Whereas the SREBP2 protein acts to increase expression of genes involved in cholesterol synthesis and uptake (eg, Ldlr, Hmgcs, and Hmgcr), miR-33 inhibits gene pathways involved in cholesterol ester hydrolysis and free cholesterol export from the cell, including intracellular trafficking and cholesterol efflux, and as described herein, autophagy and lysosomal function. Seo et al 45 demonstrated that SREBP-2 activates autophagy genes during sterol depletion and suggested that SREBP-2 activation provides the cell with lipids from 3 sources: de novo biosynthesis, lipoprotein uptake, and lipid droplet mobilization through lipophagy. Conversely, we find that miR-33, which is cotranscribed with SREBP-2, can restrict cholesterol mobilization from lipid droplets by inhibiting autophagy. It is thus possible that coregulation of miR-33 along with SREBP-2 could provide a negative feedback regulation of this transcription factor and allows for finetuning of the autophagy pathway, although the precise interplay of SREBP-2 and miR-33 to regulate autophagy remains to be fully elucidated. This miR-33/SREBP2 circuit provides an integrated system to boost cellular cholesterol levels during times of cholesterol demand. However, miR-33 expression in atherosclerotic macrophages may contribute to pathological processes, such as reducing autophagy and cholesterol efflux, which contribute to foam cell dysfunction. Although the mechanisms that drive miR-33 expression in atheroma are not yet known, 44 we recently reported that miR-33 is induced by M tuberculosis through an NFkB-dependent mechanism 30 raising the possibility that endogenous atherosclerotic ligands that activate NFkB may contribute. Strategies that inhibit this expression of miR-33 in plaque macrophages would provide a powerful approach to restore macrophage function in atherosclerosis by increasing interrelated pathways involved in autophagy, lysosomal function, cholesterol trafficking, and immunometabolism.
